North China Pharmaceutical Co Ltd
North China Pharmaceutical Company.Ltd engages in the research and development, production, and sales of pharmaceutical products in China and internationally. The company primarily offers anti-infective drugs, biotechnology drugs, cardiovascular cerebrovascular, immunomodulators, and vitamins and health products. It also provides chemical pharmaceuticals; and biological, agricultural, and veterin… Read more
North China Pharmaceutical Co Ltd (600812) - Net Assets
Latest net assets as of September 2025: CN¥6.67 Billion CNY
Based on the latest financial reports, North China Pharmaceutical Co Ltd (600812) has net assets worth CN¥6.67 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥21.54 Billion) and total liabilities (CN¥14.86 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.67 Billion |
| % of Total Assets | 30.99% |
| Annual Growth Rate | 6.16% |
| 5-Year Change | -5.4% |
| 10-Year Change | 26.66% |
| Growth Volatility | 41.77 |
North China Pharmaceutical Co Ltd - Net Assets Trend (1993–2024)
This chart illustrates how North China Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for North China Pharmaceutical Co Ltd (1993–2024)
The table below shows the annual net assets of North China Pharmaceutical Co Ltd from 1993 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.67 Billion | +6.45% |
| 2023-12-31 | CN¥6.27 Billion | +0.67% |
| 2022-12-31 | CN¥6.23 Billion | -11.24% |
| 2021-12-31 | CN¥7.02 Billion | -0.54% |
| 2020-12-31 | CN¥7.06 Billion | +25.45% |
| 2019-12-31 | CN¥5.62 Billion | +2.03% |
| 2018-12-31 | CN¥5.51 Billion | +4.38% |
| 2017-12-31 | CN¥5.28 Billion | -0.20% |
| 2016-12-31 | CN¥5.29 Billion | +0.41% |
| 2015-12-31 | CN¥5.27 Billion | +0.45% |
| 2014-12-31 | CN¥5.25 Billion | +26.54% |
| 2013-12-31 | CN¥4.15 Billion | -0.77% |
| 2012-12-31 | CN¥4.18 Billion | +217.99% |
| 2011-12-31 | CN¥1.31 Billion | +11.19% |
| 2010-12-31 | CN¥1.18 Billion | +32.64% |
| 2009-12-31 | CN¥890.92 Million | -46.66% |
| 2008-12-31 | CN¥1.67 Billion | +14.74% |
| 2007-12-31 | CN¥1.46 Billion | +4.72% |
| 2006-12-31 | CN¥1.39 Billion | -4.66% |
| 2005-12-31 | CN¥1.46 Billion | -15.22% |
| 2004-12-31 | CN¥1.72 Billion | -37.58% |
| 2003-12-31 | CN¥2.76 Billion | +3.28% |
| 2002-12-31 | CN¥2.67 Billion | -1.23% |
| 2001-12-31 | CN¥2.70 Billion | -0.10% |
| 2000-12-31 | CN¥2.70 Billion | +1.59% |
| 1999-12-31 | CN¥2.66 Billion | +39.21% |
| 1998-12-31 | CN¥1.91 Billion | -0.88% |
| 1997-12-31 | CN¥1.93 Billion | +38.43% |
| 1996-12-31 | CN¥1.39 Billion | +18.88% |
| 1995-12-31 | CN¥1.17 Billion | +0.17% |
| 1994-12-31 | CN¥1.17 Billion | +11.95% |
| 1993-12-31 | CN¥1.05 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to North China Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 489.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥1.72 Billion | 31.84% |
| Other Comprehensive Income | CN¥364.34 Million | 6.76% |
| Other Components | CN¥3.84 Billion | 71.24% |
| Total Equity | CN¥5.39 Billion | 100.00% |
North China Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of North China Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangdong Eastone Century Technology Co Ltd
SHE:300310
|
$598.80 Million |
|
Jiangmen iDear-Hanyu Electrical Joint-Stock Co Ltd
SHE:300403
|
$598.99 Million |
|
Clas Ohlson AB ser. B
LSE:0GQE
|
$599.03 Million |
|
Italmobiliare S.p.A.
LSE:0RP4
|
$599.08 Million |
|
Toyobo Co. Ltd
F:TO7
|
$598.63 Million |
|
Rumble Inc.
NASDAQ:RUM
|
$598.34 Million |
|
KIWETINOHK ENERGY
F:Y9B
|
$598.25 Million |
|
Asana Inc
NYSE:ASAN
|
$598.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in North China Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,315,303,557 to 5,389,402,984, a change of 74,099,427 (1.4%).
- Net income of 126,992,374 contributed positively to equity growth.
- Dividend payments of 469,067,063 reduced retained earnings.
- Other comprehensive income increased equity by 15,092,034.
- Other factors increased equity by 401,082,082.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥126.99 Million | +2.36% |
| Dividends Paid | CN¥469.07 Million | -8.7% |
| Other Comprehensive Income | CN¥15.09 Million | +0.28% |
| Other Changes | CN¥401.08 Million | +7.44% |
| Total Change | CN¥- | 1.39% |
Book Value vs Market Value Analysis
This analysis compares North China Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.81x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.61x to 1.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-12-31 | CN¥1.01 | CN¥5.69 | x |
| 1994-12-31 | CN¥1.13 | CN¥5.69 | x |
| 1995-12-31 | CN¥1.13 | CN¥5.69 | x |
| 1996-12-31 | CN¥1.33 | CN¥5.69 | x |
| 1997-12-31 | CN¥1.80 | CN¥5.69 | x |
| 1998-12-31 | CN¥1.78 | CN¥5.69 | x |
| 1999-12-31 | CN¥2.42 | CN¥5.69 | x |
| 2000-12-31 | CN¥2.45 | CN¥5.69 | x |
| 2001-12-31 | CN¥2.37 | CN¥5.69 | x |
| 2002-12-31 | CN¥1.43 | CN¥5.69 | x |
| 2003-12-31 | CN¥1.46 | CN¥5.69 | x |
| 2004-12-31 | CN¥0.89 | CN¥5.69 | x |
| 2005-12-31 | CN¥0.73 | CN¥5.69 | x |
| 2006-12-31 | CN¥1.14 | CN¥5.69 | x |
| 2007-12-31 | CN¥1.21 | CN¥5.69 | x |
| 2008-12-31 | CN¥1.42 | CN¥5.69 | x |
| 2009-12-31 | CN¥0.78 | CN¥5.69 | x |
| 2010-12-31 | CN¥0.99 | CN¥5.69 | x |
| 2011-12-31 | CN¥1.12 | CN¥5.69 | x |
| 2012-12-31 | CN¥3.66 | CN¥5.69 | x |
| 2013-12-31 | CN¥2.96 | CN¥5.69 | x |
| 2014-12-31 | CN¥3.38 | CN¥5.69 | x |
| 2015-12-31 | CN¥3.28 | CN¥5.69 | x |
| 2016-12-31 | CN¥3.22 | CN¥5.69 | x |
| 2017-12-31 | CN¥3.39 | CN¥5.69 | x |
| 2018-12-31 | CN¥3.32 | CN¥5.69 | x |
| 2019-12-31 | CN¥3.41 | CN¥5.69 | x |
| 2020-12-31 | CN¥3.76 | CN¥5.69 | x |
| 2021-12-31 | CN¥3.57 | CN¥5.69 | x |
| 2022-12-31 | CN¥3.09 | CN¥5.69 | x |
| 2023-12-31 | CN¥3.26 | CN¥5.69 | x |
| 2024-12-31 | CN¥3.14 | CN¥5.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently North China Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.29%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 3.98x
- Recent ROE (2.36%) is below the historical average (3.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | 15.34% | 17.74% | 0.62x | 1.40x | CN¥55.82 Million |
| 1994 | 17.74% | 18.06% | 0.62x | 1.58x | CN¥90.54 Million |
| 1995 | 20.46% | 16.98% | 0.64x | 1.89x | CN¥121.74 Million |
| 1996 | 15.03% | 13.13% | 0.56x | 2.03x | CN¥68.90 Million |
| 1997 | 10.34% | 13.14% | 0.42x | 1.88x | CN¥6.24 Million |
| 1998 | 5.44% | 7.51% | 0.34x | 2.13x | CN¥-83.73 Million |
| 1999 | 4.15% | 6.36% | 0.29x | 2.23x | CN¥-146.24 Million |
| 2000 | 3.82% | 4.10% | 0.40x | 2.36x | CN¥-156.12 Million |
| 2001 | 4.55% | 3.91% | 0.39x | 3.01x | CN¥-133.04 Million |
| 2002 | 5.34% | 4.36% | 0.43x | 2.84x | CN¥-114.10 Million |
| 2003 | 8.65% | 6.04% | 0.49x | 2.90x | CN¥-33.85 Million |
| 2004 | 3.87% | 1.42% | 0.54x | 5.01x | CN¥-93.14 Million |
| 2005 | -14.96% | -4.72% | 0.57x | 5.58x | CN¥-313.10 Million |
| 2006 | -1.02% | -0.30% | 0.57x | 5.95x | CN¥-129.79 Million |
| 2007 | 4.86% | 1.43% | 0.64x | 5.35x | CN¥-64.11 Million |
| 2008 | 19.10% | 5.69% | 0.70x | 4.81x | CN¥133.03 Million |
| 2009 | -46.16% | -7.44% | 0.68x | 9.16x | CN¥-447.76 Million |
| 2010 | 23.75% | 2.35% | 1.13x | 8.96x | CN¥139.99 Million |
| 2011 | 10.90% | 1.02% | 1.09x | 9.84x | CN¥10.26 Million |
| 2012 | 0.44% | 0.16% | 0.82x | 3.33x | CN¥-389.42 Million |
| 2013 | 0.34% | 0.11% | 0.85x | 3.60x | CN¥-390.26 Million |
| 2014 | 0.74% | 0.41% | 0.60x | 2.99x | CN¥-481.84 Million |
| 2015 | 1.19% | 0.80% | 0.49x | 3.02x | CN¥-465.99 Million |
| 2016 | 1.02% | 0.67% | 0.49x | 3.10x | CN¥-476.86 Million |
| 2017 | 0.35% | 0.24% | 0.45x | 3.23x | CN¥-511.88 Million |
| 2018 | 2.77% | 1.64% | 0.51x | 3.29x | CN¥-393.60 Million |
| 2019 | 3.10% | 1.50% | 0.62x | 3.33x | CN¥-383.86 Million |
| 2020 | 1.59% | 0.85% | 0.48x | 3.91x | CN¥-515.11 Million |
| 2021 | 0.31% | 0.18% | 0.42x | 4.10x | CN¥-589.82 Million |
| 2022 | -13.00% | -6.56% | 0.49x | 4.00x | CN¥-1.22 Billion |
| 2023 | 0.09% | 0.05% | 0.48x | 3.94x | CN¥-526.64 Million |
| 2024 | 2.36% | 1.29% | 0.46x | 3.98x | CN¥-411.95 Million |
Industry Comparison
This section compares North China Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| North China Pharmaceutical Co Ltd (600812) | CN¥6.67 Billion | 15.34% | 2.23x | $598.70 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |